Back to Stakeholders

Enterprise Intelligence

Quarterly psychedelic drug-development briefing

Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.

Browse briefingsOpen Q2 briefing

Thermo Fisher Scientific is a global life-sciences and laboratory-services company headquartered in Waltham, Massachusetts, formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Its contract development and manufacturing arm (including Patheon) is engaged by psychedelic drug developers for US-based clinical supply and potential commercial manufacturing, alongside its broad reagents, instruments and analytical-services portfolio.

Manufacturing Snapshot

Established CDMO / Manufacturer

Scope & Capabilities

API ProductionDrug Product ManufacturingAnalytical / QC TestingRegulatory / CMC SupportCDMO Services

Supply Use Cases

Clinical TrialsCommercial / Licensed SupplyPartner-Only Supply

GxP / Compliance

cGMPGeneral GxP

Facilities & Access

Cybin disclosures cite Thermo Fisher pharma-services manufacturing support in South Carolina (drug substance) and Ohio (capsule drug product).

Manufacturing Details

Supported Substances

Cybin disclosed engagement of Thermo Fisher for Phase 3 clinical supply and potential commercial manufacturing for CYB003 (deuterated psilocin program).

Manufacturing Sources

Cybin Engages Thermo Fisher for CYB003 U.S.-Based Manufacturing

https://www.businesswire.com/news/home/20250515803642/en/Cybin-Engages-Thermo-Fisher-Scientific-to-Provide-U.S.-Based-Manufacturing-for-its-CYB003-Program-for-the-Adjunctive-Treatment-of-Major-Depressive-Disorder

Quick Facts

Founded
2006
HQ
United States
Website
Visit